Literature DB >> 25792260

Secondary pharmacology data to assess potential off-target activity of new drugs: a regulatory perspective.

Thomas Papoian1, Haw-Jyh Chiu2, Ikram Elayan3, Gowraganahalli Jagadeesh1, Imran Khan3, Adebayo A Laniyonu4, Cindy Xinguang Li5, Muriel Saulnier1, Natalie Simpson2, Baichun Yang1.   

Abstract

Mesh：

Year:  2015        PMID： 25792260     DOI： 10.1038/nrd3845-c1

Source DB:  PubMed          Journal:  Nat Rev Drug Discov        ISSN： 1474-1776            Impact factor:   84.694


× No keyword cloud information.
  7 in total

1.  Are the Protective Effects of SGLT2 Inhibitors a "Class-Effect" or Are There Differences between Agents?

Authors:  Darren W Schmidt; Christos Argyropoulos; Namita Singh
Journal:  Kidney360       Date:  2021-02-05

Review 2.  The emerging role of mass spectrometry-based proteomics in drug discovery.

Authors:  Felix Meissner; Jennifer Geddes-McAlister; Matthias Mann; Marcus Bantscheff
Journal:  Nat Rev Drug Discov       Date:  2022-03-29       Impact factor: 112.288

3.  Relevance of physicochemical properties and functional pharmacology data to predict the clinical safety profile of direct oral anticoagulants.

Authors:  Charles J Ferro; Fay Solkhon; Zahraa Jalal; Abdullah M Al-Hamid; Alan M Jones
Journal:  Pharmacol Res Perspect       Date:  2020-06

Review 4.  A Selective and Brain Penetrant p38αMAPK Inhibitor Candidate for Neurologic and Neuropsychiatric Disorders That Attenuates Neuroinflammation and Cognitive Dysfunction.

Authors:  Saktimayee M Roy; George Minasov; Ottavio Arancio; Laura W Chico; Linda J Van Eldik; Wayne F Anderson; Jeffrey C Pelletier; D Martin Watterson
Journal:  J Med Chem       Date:  2019-04-23       Impact factor: 7.446

5.  Clinical Implications and Translation of an Off-Target Pharmacology Profiling Hit: Adenosine Uptake Inhibition In Vitro.

Authors:  Hamid R Amouzadeh; Isaiah Dimery; Jonathan Werner; Gataree Ngarmchamnanrith; Michael J Engwall; Hugo M Vargas; Deborah Arrindell
Journal:  Transl Oncol       Date:  2019-07-19       Impact factor: 4.243

6.  Rationalizing Secondary Pharmacology Screening Using Human Genetic and Pharmacological Evidence.

Authors:  Aimee M Deaton; Fan Fan; Wei Zhang; Phuong A Nguyen; Lucas D Ward; Paul Nioi
Journal:  Toxicol Sci       Date:  2019-02-01       Impact factor: 4.849

7.  A proteomic platform to identify off-target proteins associated with therapeutic modalities that induce protein degradation or gene silencing.

Authors:  Xin Liu; Ye Zhang; Lucas D Ward; Qinghong Yan; Tanggis Bohnuud; Rocio Hernandez; Socheata Lao; Jing Yuan; Fan Fan
Journal:  Sci Rep       Date:  2021-08-04       Impact factor: 4.379
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.